Black Diamond Therapeutics
BDTX
104 hedge funds and large institutions have $92M invested in Black Diamond Therapeutics in 2025 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 12 closing their positions.
180% more call options, than puts
Call options by funds: $657K | Put options by funds: $235K
125% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 12
44% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 25
14% more funds holding
Funds holding: 91 → 104 (+13)
1.67% less ownership
Funds ownership: 68.11% → 66.45% (-1.7%)
37% less capital invested
Capital invested by funds: $147M → $92M (-$55M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$4.07M |
| 2 |
Jane Street
New York
|
+$2.57M |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$1.85M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.81M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$16.6M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$7.85M |
| 3 |
Millennium Management
New York
|
-$1.96M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.31M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.16M |
BDTX Hedge Fund Activity: Q4 2025 in Review
104 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q4 2025, worth a combined $92M — down 37% from $147M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new BDTX positions and 12 closed out — a net gain of 15 holders — while 36 added to existing stakes and 25 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $4.07M. The largest seller was Vestal Point Capital, cutting an estimated $16.6M.
- 104 institutional investors held Black Diamond Therapeutics (BDTX) as of Q4 2025, up from 91 in Q3 2025.
- Funds reported $92M of Black Diamond Therapeutics stock for Q4 2025, down 37% quarter-over-quarter.
- 27 funds opened new Black Diamond Therapeutics positions in Q4 2025 and 12 closed out, a net change of +15 holders.
- The largest Black Diamond Therapeutics buyer in Q4 2025 was Acadian Asset Management, an estimated $4.07M added.
- The largest Black Diamond Therapeutics seller in Q4 2025 was Vestal Point Capital, an estimated $16.6M sold.
Based on aggregated 13F filings for Q4 2025.